Alembic Pharmaceuticals Gains 4.62%: 6 Key Factors Driving the Week’s Momentum

29 June 2026: Week Opens Steady Amid Sector Volatility

Alembic Pharmaceuticals began the week at Rs.786.25, with a volume of 62,253 shares traded. The Sensex closed at 35,960.98, setting a baseline for the week’s performance. The stock was positioned well above its 52-week low of Rs.635.30 but remained distant from its 52-week high of Rs.1,107.80, reflecting ongoing sector volatility and investor caution.

30 June 2026: Technical Momentum Shifts Spark 4.74% Rally

The stock surged 4.74% to close at Rs.823.55, outperforming the Sensex which declined marginally by 0.01% to 35,958.71. This rally was driven by a notable shift in technical momentum from sideways to mildly bearish, as daily moving averages indicated a cautious stance. Despite the short-term gain, mixed signals from MACD and RSI suggested a complex momentum environment. Weekly MACD remained mildly bullish, while monthly MACD turned bearish, highlighting divergent trends across timeframes.

1 July 2026: Sideways Trend Emerges with Modest Gains

On 1 July, Alembic Pharmaceuticals edged up 0.49% to Rs.827.55, with the Sensex gaining 0.45% to 36,119.01. The technical trend transitioned from mildly bearish to sideways, signalling consolidation. Weekly indicators such as the KST oscillator and Bollinger Bands showed bullish tendencies, while monthly indicators remained bearish. On-Balance Volume (OBV) was bullish on both weekly and monthly charts, suggesting accumulation despite mixed price action.

2 July 2026: Valuation Upgrade Amid Mildly Bearish Technical Shift

The stock closed at Rs.815.20, down 1.49% from the previous day, while the Sensex advanced 0.71% to 36,376.02. Technical momentum shifted back to mildly bearish, with daily moving averages crossing lower and monthly MACD remaining bearish. However, weekly MACD and Bollinger Bands stayed bullish, reflecting short-term strength. Valuation metrics improved significantly, with the price-to-earnings (P/E) ratio dropping to 22.23 and price-to-book value (P/BV) at 2.88, marking a shift to very attractive territory compared to expensive peers such as Ajanta Pharma and J B Chemicals.

Enterprise value to EBITDA stood at 15.68, well below sector leaders like Wockhardt and Neuland Laboratories. The PEG ratio of 0.79 further underscored the stock’s relative value. Despite modest returns on capital employed (11.59%) and equity (12.93%), these valuation improvements suggested renewed price appeal amid mixed fundamentals.

3 July 2026: MarketsMOJO Upgrades to Hold on Improved Technicals and Valuation

On the final trading day of the week, Alembic Pharmaceuticals closed at Rs.822.60, gaining 0.91%, while the Sensex rose 0.15% to 36,431.45. MarketsMOJO upgraded the stock’s rating from Sell to Hold, reflecting stabilisation in technical indicators and enhanced valuation attractiveness. The technical trend settled into a sideways pattern, with weekly MACD and Bollinger Bands bullish but monthly indicators still bearish. On-Balance Volume remained positive, signalling accumulation.

Financial performance remained flat, with operating profit to interest coverage at 10.10 times and PBDIT at Rs.227.92 crores, the lowest quarterly figure recently. Despite this, the company’s strong debt servicing ability (Debt to EBITDA ratio of 1.28) and institutional holdings of 20.41% lent confidence. The Mojo Score rose to 51.0, supporting the Hold rating.

Daily Price Comparison: Alembic Pharmaceuticals vs Sensex

Key Takeaways

Outperformance Amid Mixed Technicals: Alembic Pharmaceuticals outpaced the Sensex with a 4.62% weekly gain versus 1.31%, driven by early-week rallies and sustained accumulation despite technical divergences.

Technical Momentum Divergence: Weekly indicators such as MACD and Bollinger Bands showed bullish signals, while monthly momentum remained bearish, reflecting a complex interplay of short-term optimism and longer-term caution.

Valuation Re-rating: The stock’s P/E ratio improved to 22.23 and P/BV to 2.88, marking a shift to very attractive valuation levels relative to expensive sector peers, supported by a PEG ratio below 1.

Rating Upgrade to Hold: MarketsMOJO’s upgrade from Sell to Hold on 2 July 2026 was driven by stabilising technical trends, improved valuation, and steady financial metrics despite flat recent earnings.

Financial Stability Amid Flat Performance: Operating profit margins and interest coverage ratios showed pressure, but strong debt servicing and institutional confidence provided a foundation for cautious optimism.

Volatility and Consolidation: The stock’s price action reflected a consolidation phase with key support near Rs.807 and resistance around Rs.847, highlighting the importance of monitoring technical levels for future direction.

Conclusion

Alembic Pharmaceuticals Ltd. demonstrated a resilient performance in the week ending 3 July 2026, with a 4.62% gain that outpaced the broader market. The week was characterised by shifting technical momentum, a significant valuation upgrade, and a rating revision to Hold by MarketsMOJO. While short-term technical indicators suggest emerging strength, longer-term momentum remains cautious, underscoring the stock’s transitional phase.

Investors should consider the improved valuation metrics and stabilising technical signals alongside the company’s flat recent financial performance and sector volatility. The Hold rating reflects a balanced outlook, recommending vigilance and measured exposure rather than aggressive positioning. Monitoring key technical levels and upcoming financial results will be critical in assessing Alembic Pharmaceuticals’ trajectory in the evolving pharmaceuticals landscape.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →